Lophora is a drug-development start-up developing new rapid-acting drugs for central nervous system diseases including treatment-resistant depression.
Founded in 2017 Lophora has successfully finished initial characterization of our lead-candidate through PoC funding granted by the BioInovation institute (BII) and now seek funding toward IND status and first in human trials.
We believe we hold a unique position in the market for anti-depressant therapies of the future. The company seeks to mature lead-candidate LPH-5 through pre-clinical operations, toward first in human trials by the end of 2021. Given our unique technology and knowledge of the field, we are confident that we are moving ahead of a global market shift towards medically aided psychotherapy as a treatment for TRD.
Interested in the antidepressant therapy of the future?
Invested in bringing relief from despair